CRG-002

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameCRG-002
Drug Alias NameiPSC衍生β-胰岛细胞CRG-002
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsType 3c DiabetesDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Celregen Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Celregen Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsType 3c DiabetesDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A